Answer
It is unknown whether filgrastim or its metabolites pass into human milk; risk to newborns or infants cannot be excluded, so a decision about stopping breast-feeding or stopping or avoiding filgrastim must weigh breast-feeding benefits for the child against treatment benefits for the woman.
Sources for this answer
- Nivestim 12 MU/ 0.2 ml solution for injection/infusionPfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 23Document updated
Sources checked